Abstract:Endothelial Nitric oxide (NO) production is dependent on adequate cellular tetrahydrobiopterin (BH 4 ), a key cofactor for endothelial NO syntheses (eNOS). Reduction of BH 4 levels is reported in diseased vessels and plays a causal role in the development of eNOS uncoupling. However, the mechanisms that lead to BH 4 reduction are not entirely understood. Here we report that angiotensin-II (Ang II) reduced tetrahydrobiopterin (BH 4 ) and eNOS uncoupling by peroxynitrite ONOO − )-triggered proteasome activation. Compared to control, exposure of human umbilical vein endothelial cells (HUVEC) to angiotensin II (Ang II, 100nM) for 6h significantly decreased the levels of total biopterins (BH 4 plus BH 2 ) and BH 4 (−22.0 4.6%, n= 3, p<0.01), indicating decreased synthesis of biopterins. In parallel, Ang II but not vehicle significantly reduced the levels of GTP-cyclohydrolase (GTPCH), a rate-limiting enzyme for de novo synthesis of biopterins, and dihydrofolate reductase (DHFR), a crucial enzyme for BH 4 recycle from BH 2 . Ang II but not vehicle significantly increased the 26S proteasome activity. In addition, administration of proteasome inhibitors, MG132, abolished the Ang II-induced reduction of both GTPCH and DHFR. While Ang II significantly increased O 2 − , the scavenging of O 2 − by Tempol (SOD mimetic), or inhibition of NOS with N -nitro-L-arginine methyl ester hydrochloride (L-NAME) (1mM) significantly attenuated Ang II-induced both 26S proteasome activation and the reduction of both GTPCH and DHFR, suggesting that Ang II via endogenous ONOO − causes 26S proteasome-dependent degradation of both GTPCH and DHFR. Moreover, inhibition of NAD(P)H oxidase with either apocynin or by overexpression of p67 phox -dominant negative mutants ablated Ang II-induced proteasome activation and degradation of both GTPCH and DHFR. Finally, treatment of mice aorta ex vivo with MG132 (0.5 μM for 1h followed by Ang II for 12h) reversed the Ang II-induced reduction of GTPCH, DHFR and BH 4 , and increased acetylcholine-induced endothelium-dependent relaxation. We conclude that Ang II activates NAD(P)H oxidase to release O 2 . − and ONOO − , which activate 26S proteasome resulting in increased degradation of both GTPCH and DHFR, two key enzymes in controlling the levels of BH 4 .

Abstract 15412: Novel Treatment of Hypertension by Specifically Targeting E2F for the Restoration of Endothelial Dihydrofolate Reductase and Enos Function under Oxidative Stress

Novel Treatment of Hypertension by Specifically Targeting E2F for Restoration of Endothelial Dihydrofolate Reductase and Enos Function under Oxidative Stress

Progress on the Treatment for Hypertension of Epoxide Hydrolase and Its Mechanisms

Stimulation of GSH synthesis to prevent oxidative stress-induced apoptosis by hydroxytyrosol in human retinal pigment epithelial cells: activation of Nrf2 and JNK-p62/SQSTM1 pathways.

Induction of heme oxygenase-1 ameliorates vascular dysfunction in streptozotocin-induced type 2 diabetic rats (Reprinted from Vascular Pharmacology, 61, pg 16-24)

Retracted: the Correlation Between Angiogenesis and Abnormal Expression of SERCA2a, Phospholamban and the Endothelin Pathway in Heart Failure, and Improvement by Puerarin

Heme oxygenase-1 ameliorates oxidative stress-induced endothelial senescence via regulating endothelial nitric oxide synthase activation and coupling

Gene Transfer Of Human Guanosine 5 '-Triphosphate Cyclohydrolase I Restores Vascular Tetrahydrobiopterin Level And Endothelial Function In Low Renin Hypertension

Melatonin ameliorates ischemic-like injury-evoked nitrosative stress: Involvement of HtrA2/PED pathways in endothelial cells.

Inhibition of Mitochondrial Oxidative Damage Improves Reendothelialization Capacity of Endothelial Progenitor Cells Via SIRT3 (sirtuin 3)-Enhanced SOD2 (superoxide Dismutase 2) Deacetylation in Hypertension.

Mechanisms and Consequences of Endothelial Nitric Oxide Synthase Dysfunction in Hypertension

Abstract 15882: Ablation of E2F3 in Endothelial Cells Impairs the Functional Recovery of Heart and Limb from Ischemic Injury

Regulation of Vascular Contractility and Blood Pressure by the E2F2 Transcription Factor

Abstract 109: Protective Effects of Nuclear Factor E2-related Factor 2 Activation on Angiotensin II Induced Microvascular Endothelial Dysfunction

Soluble Epoxide Hydrolase Inhibitor t-AUCB Ameliorates Vascular Endothelial Dysfunction by Influencing the NF-κB/miR-155-5p/eNOS/NO/IκB Cycle in Hypertensive Rats

E2F1 Suppresses Oxidative Metabolism and Endothelial Differentiation of Bone Marrow Progenitor Cells.

Homoeriodictyol Protects Human Endothelial Cells Against Oxidative Insults Through Activation of Nrf2 and Inhibition of Mitochondrial Dysfunction.

PPARδ Agonist Prevents Endothelial Dysfunction Via Induction of Dihydrofolate Reductase Gene and Activation of Tetrahydrobiopterin Salvage Pathway

Abstract 257: Oxidative Stress Induces Endothelial Dysfunction: Role of Ubiquitin-Proteasome System

Endothelial Nitric Oxide Synthase–Derived Nitric Oxide Prevents Dihydrofolate Reductase Degradation Via Promoting S-Nitrosylation

IMPAIRED SOD2 ACTIVITY LINKED WITH EXCESSIVE MITOCHONDRIAL SUPEROXIDE IS RESPONSIBLE FOR DIMINISHED RE-ENDOTHELIALIZATION OF ENDOTHELIAL PROGENITOR CELLS IN HYPERTENSION